Mouse myocardial first-pass perfusion MR imaging

Bram F Coolen1, Rik P M Moonen, Leonie E M Paulis

  • 1Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

Insights

This study introduces a new cardiac MRI method for assessing mouse heart blood flow. It accurately detects reduced perfusion in infarct regions, aiding preclinical research in ischemic heart disease.

Area of Science:

  • Cardiovascular Imaging
  • Preclinical Research
  • Magnetic Resonance Imaging

Background:

  • Assessing myocardial perfusion is crucial for understanding ischemic heart disease.
  • Mouse models are vital for preclinical cardiovascular research.
  • Advanced imaging techniques are needed for high-resolution cardiac assessment in mice.

Purpose of the Study:

  • To develop and validate a first-pass myocardial perfusion sequence for mouse cardiac MRI.
  • To assess the reproducibility and accuracy of the technique in detecting perfusion deficits.
  • To establish a tool for preclinical studies of ischemic heart disease.

Main Methods:

  • Utilized a segmented, ECG-triggered acquisition with parallel imaging acceleration.
  • Captured the first pass of a Gadolinium-DTPA (Gd-DTPA) contrast agent bolus.
  • Achieved a temporal resolution of 300-400 milliseconds.
  • Applied the method in healthy mice and mice with induced coronary artery occlusion.

Main Results:

  • Demonstrated excellent reproducibility of semiquantitative perfusion values in healthy mouse myocardium.
  • Identified significantly decreased myocardial perfusion values in infarct regions (0.05 ± 0.02) compared to remote myocardium (0.20 ± 0.04).
  • Showed strong correlation between areas of decreased perfusion and infarct areas on delayed-enhancement scans.

Conclusions:

  • The developed first-pass myocardial perfusion MRI sequence is a valuable addition to the preclinical research toolbox.
  • This technique enables accurate, reproducible assessment of myocardial perfusion in mouse models of ischemic heart disease.
  • The findings support the use of this method for evaluating therapeutic interventions in preclinical settings.